Citalopram, methylphenidate, or their combination in geriatric depression: A randomized, double-blind, placebo-controlled trial

American Journal of Psychiatry

Volumn 172, Issue 6, 2015, Pages 561-569

  Lavretsky, Helen ^a,b,c   Reinlieb, Michelle ^a,b,c   Cyr, Natalie St ^a,b,c   Siddarth, Prabha ^a,b,c   Ercoli, Linda M ^a,b,c   Senturk, Damla ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; METHYLPHENIDATE; PLACEBO;

AGED; ANXIETY; APATHY; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COGNITION; CONTROLLED STUDY; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GERIATRIC DEPRESSION; GERIATRIC DISORDER; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REMISSION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ANXIETY DISORDERS; COGNITION DISORDERS; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DEPRESSIVE DISORDER, MAJOR; DRUG EFFECTS; MIDDLE AGED; PERSONALITY ASSESSMENT; PSYCHOLOGY; PSYCHOMETRY; STATISTICS AND NUMERICAL DATA;

AGED; ANXIETY DISORDERS; APATHY; CITALOPRAM; COGNITION DISORDERS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHYLPHENIDATE; MIDDLE AGED; PERSONALITY ASSESSMENT; PSYCHOMETRICS; QUALITY OF LIFE;

EID: 84979862393     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2014.14070889     Document Type: Article

References (41)

1. Alexopoulos GS, Young RC, Abrams RC, et al: Chronicity and relapse in geriatric depression. Biol Psychiatry 1989; 26:551-564.
2. Reynolds CF 3rd, Dew MA, Pollock BG, et al: Maintenance treatment of major depression in old age. N Engl J Med 2006; 354:1130-1138.
3. Nelson JC, Delucchi K, Schneider LS: Efficacy of second generation antidepressants in late-life depression: A meta- Analysis of the evidence. Am J Geriatr Psychiatry 2008; 16:558-567.
4. Nelson JC, Delucchi KL, Schneider LS: Moderators of outcome in late-life depression: A patient-level meta- Analysis. Am J Psychiatry 2013; 170:651-659.
5. Rutherford BR, Roose SP: A model of placebo response in antidepressant clinical trials. Am J Psychiatry 2013; 170:723-733.
6. Sackeim HA, Roose SP, Burt T: Optimal length of antidepressant trials in late-life depression. J Clin Psychopharmacol 2005; 25(suppl 1):S34-S37.
7. Alexopoulos GS, Kiosses DN, Heo M, et al: Executive dysfunction and the course of geriatric depression. Biol Psychiatry 2005; 58:204-210.
8. Sneed JR, Culang ME, Keilp JG, et al: Antidepressant medicationand executive dysfunction: A deleterious interaction in late-life depression. Am J Geriatr Psychiatry 2010; 18:128-135.
9. Kiosses DN, Alexopoulos GS: IADL functions, cognitive deficits, and severity of depression: A preliminary study. Am J Geriatr Psychiatry 2005; 13:244-249.
10. Petersen RC, Smith GE, Waring SC, et al: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56:303-308.
11. Bhalla RK, Butters MA, Becker JT, et al: Patterns of mild cognitive impairment after treatment of depression inthe elderly.AmJ Geriatr Psychiatry 2009; 17:308-316.
12. Butters MA, Becker JT, Nebes RD, et al: Changes in cognitive functioning following treatment of late-life depression. Am J Psychiatry 2000; 157:1949-1954.
13. Culang ME, Sneed JR, Keilp JG, et al: Change in cognitive functioning following acute antidepressant treatment in late-life depression. Am J Geriatr Psychiatry 2009; 17:881-888.
14. Lee JS, Potter GG, Wagner HR, et al: Persistent mild cognitive impairment in geriatric depression. Int Psychogeriatr 2007; 19:125-135.
15. Nebes RD, Pollock BG, Houck PR, et al: Persistence of cognitive impairment in geriatric patients following antidepressant treatment: A randomized, double-blind clinical trial with nortriptyline and paroxetine. J Psychiatr Res 2003; 37:99-108.
16. Lavretsky H, Park S, Siddarth P, et al: Methylphenidate-enhanced antidepressant response to citalopram in the elderly: A double-blind, placebo-controlled pilot trial. Am J Geriatr Psychiatry 2006; 14:181-185.
17. Volkow ND, Gur RC, Wang GJ, et al: Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. Am J Psychiatry 1998; 155:344-349.
18. Lavretsky H, Kim MD, Kumar A, et al: Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: An open trial. J Clin Psychiatry 2003; 64:1410-1414.
19. Lavretsky H, Kumar A:Methylphenidateaugmentationof citalopram in elderly depressed patients. Am J Geriatr Psychiatry 2001; 9:298-303.
20. Satel SL, Nelson JC: Stimulants in the treatment of depression: A critical overview. J Clin Psychiatry 1989; 50:241-249.
21. Murray GB, Cassem E: Use of stimulants in depressed patients with medical illness, in Geriatric Psychopharmacology. Edited by Nelson JG. New York, Marcel Decker, 1998, pp 245-258.
22. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62.
23. Folstein MF, Folstein SE, McHugh PR: "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198.
24. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: PublicationADM76-338.Washington, DC, USDepartment ofHealth, Education, and Welfare, 1976, pp 218-222.
25. Montgomery SA, Åsberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382-389.
26. Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959; 32:50-55.
27. Marin RS, Biedrzycki RC, Firinciogullari S: Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res 1991; 38:143-162.
28. Truelsen T, Lindenstrøm E, Boysen G: Comparison of probability of stroke between the Copenhagen City Heart Study and the Framingham Study. Stroke 1994; 25:802-807.
29. Miller MD, Paradis CF, Houck PR, et al: Rating chronic medical illness burden in geropsychiatric practice and research: Application of the Cumulative Illness Rating Scale. Psychiatry Res 1992; 41: 237-248.
30. Brazier JE, Harper R, Jones NM, et al: Validating the SF-36 health survey questionnaire: new outcome measure for primary care. Br Med J 1992; 305:160-164.
31. Lezak MD, Howieson DB, Loring DW: Neuropsychological Assessment, 4th ed. New York, Oxford University Press, 2004.
32. Selnes OA, Jacobson L, Machado AM, et al: Normativedata for a brief neuropsychological screening battery: Multicenter AIDS Cohort Study. Percept Mot Skills 1991; 73:539-550.
33. Van Gorp WG, Satz P, Mitrushina M: Neuropsychological processes associated with normal aging. Dev Neuropsychol 1990; 6: 279-290.
34. Lingjaerde O, Ahlfors UG, Bech P, et al: The UKU Side Effect Rating Scale: A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic- Treated patients. Acta Psychiatr Scand Suppl 1987; 334:1-100.
35. Darvill FT Jr, Woolley S:Double blind evaluation ofmethylphenidate (Ritalin) hydrochloride: its use inthemanagement of institutionalized geriatric patients. J Am Med Assoc 1959; 169:1739-1741.
36. Masand P, Pickett P, Murray GB: Psychostimulants for secondary depression in medical illness. Psychosomatics 1991; 32:203-208.
37. Nelson JC: Augmentation strategies for treatment of unipolar major depression. Mod Probl Pharmacopsychiatry 1997; 25:34-55.
38. Woods SW, Tesar GE, Murray GB, et al: Psychostimulant treatment of depressive disorders secondary to medical illness. J Clin Psychiatry 1986; 47:12-15.
39. Doraiswamy PM, Krishnan KR, Oxman T, et al: Does antidepressant therapy improve cognition in elderly depressed patients? J Gerontol A Biol Sci Med Sci 2003; 58:M1137-M1144.
40. US Food and Drug Administration: FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Aug 24, 2011 (http://www.fda.gov/drugs/drugsafety/ucm297391.htm).
41. Drye LT, Spragg D, Devanand DP, et al: Changes in QTc interval in the Citalopram for Agitation in Alzheimer's Disease (CitAD) randomized trial. PLoS ONE 2014; 9:e98426.